Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
BROOKLYN, N.Y. – Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on artificial intelligence→
